Second limitations of this research include the need for more patients with all breast cancer subtypes; third, the use of different types of antibodies and diverse conditions for immunohistochemistry; forth, not performing CD24 for economic reasons and evaluating CD44 only in the HER2-positive patients. This evidence concerns the gene CD24 and breast cancer.